These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [The evaluation of the epidemiological efficacy of 3-component inactivated influenza vaccines using an intranasal application method]. Marinich IG; Iaroshevskaia IIu; Konareva AL; Lonskaia NI; Shadrin AS; Salmin LV Zh Mikrobiol Epidemiol Immunobiol; 1993; (6):76-8. PubMed ID: 8079581 [No Abstract] [Full Text] [Related]
10. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410 [TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. Isakova-Sivak I; Rudenko L Expert Rev Vaccines; 2015; 14(10):1313-29. PubMed ID: 26289975 [TBL] [Abstract][Full Text] [Related]
12. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Forrest BD; Steele AD; Hiemstra L; Rappaport R; Ambrose CS; Gruber WC Vaccine; 2011 May; 29(20):3633-9. PubMed ID: 21440036 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042 [TBL] [Abstract][Full Text] [Related]
15. [Unresolved problems in the specific prevention of influenza]. Fridman EA; Peradze TV Tr Inst Im Pastera; 1982; 59():6-12. PubMed ID: 7187568 [No Abstract] [Full Text] [Related]
16. [The immunization of elderly people against influenza]. Bektimirov TA Vopr Virusol; 1993; 38(6):242-5. PubMed ID: 8303881 [No Abstract] [Full Text] [Related]
17. [Vaccinal prevention of influenza in children]. Zykov MP; Vasil'eva RI Tr Inst Im Pastera; 1982; 58():30-8. PubMed ID: 6764981 [No Abstract] [Full Text] [Related]
18. Development of vaccines against influenza H5. Stephenson I; Gust I; Pervikov Y; Kieny MP Lancet Infect Dis; 2006 Aug; 6(8):458-60. PubMed ID: 16870521 [No Abstract] [Full Text] [Related]
19. Comparative efficacy of inactivated and live attenuated influenza vaccines. Monto AS; Ohmit SE; Petrie JG; Johnson E; Truscon R; Teich E; Rotthoff J; Boulton M; Victor JC N Engl J Med; 2009 Sep; 361(13):1260-7. PubMed ID: 19776407 [TBL] [Abstract][Full Text] [Related]
20. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity]. Slepushkin AN; Rudenko LG; Kendal AP; Monto AS; Beliaev AL; Burtseva EI; Grigor'eva EP; Obrosova-Serova NP; Ivanova VT; Bragina VE Vopr Virusol; 1994; 39(3):129-31. PubMed ID: 8091754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]